CareDx (CDNA) Set to Announce Quarterly Earnings on Thursday

CareDx (NASDAQ:CDNA) will issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. CareDx has set its FY 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

CareDx (NASDAQ:CDNA) last posted its earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($1.97). The business had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The business’s revenue was down 20.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.34) earnings per share. On average, analysts expect CareDx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CareDx Trading Up 2.9 %

CDNA stock opened at $10.48 on Wednesday. The business’s 50-day moving average price is $9.72 and its two-hundred day moving average price is $9.43. The firm has a market cap of $542.65 million, a PE ratio of -2.96 and a beta of 1.51. CareDx has a 1-year low of $4.80 and a 1-year high of $12.93.

Analyst Ratings Changes

Several research analysts have weighed in on CDNA shares. Craig Hallum upgraded CareDx from a “hold” rating to a “buy” rating and lifted their target price for the stock from $12.00 to $15.00 in a report on Wednesday, May 1st. Stephens reiterated an “overweight” rating and set a $15.00 target price on shares of CareDx in a report on Wednesday, April 17th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.